Companiesandmarkets.com: GERD market impacted by patent expirations

LONDON--(BUSINESS WIRE)-- For the next eight years, the global market for gastroesophageal reflux disease (GERD) therapeutics is expected to decline by 2% CAGR, dropping from a 2010 valuation of $5.8 billion to $4.9 billion in 2018. According to a new report available from companiesandmarkets.com, the GERD market will be heavily impacted by patent expirations over the reporting period.

Gastroesophageal Reflux Disease (GERD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.companiesandmarkets.com/Market-Report/gastroesophageal-reflux-disease-(gerd)-therapeutics-pipeline-assessment-and-market-forecasts-to-2018-701812.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

Over the next few years all GERD therapeutics falling into the Proton Pump Inhibitors, or PPI, category will drop off patent, such as Aciphex/Pariet (rabeprazole), and Nexium (esomeprazole). As generic alternatives erode the market share of the large pharmaceutical players, the market overall will also shrink, resulting in a 2018 forecast of just under $5 million – around $1 million down on the 2010 valuation.

Over the long term, the market will balance out, as the number of patients presenting to doctors with gastroesophageal reflux disease is increasing, and those already diagnosed require anti-reflux maintenance treatment.

Therapies used to treat GERD include: Aciphex (rabeprazole sodium), Dexilant (dexlansoprazole), Nexium (esomeprazole), Prevacid (lansoprazole), Prilosec (omeprazole), Protonix (pantoprazole sodium), Zegerid (omeprazole/sodium bicarbonate), Axid (nizatidine) and Pepcid (famotidine).

These products focus on reducing production of gastric acid; neutralizing gastric acidity, encourage/improve gastric emptying; restoring function of the lower esophageal sphincter and reducing the occurrence of transient lower esophageal sphincter relaxations (TLESRs).

The market is highly competitive with limited scope for new entrants. Safety and efficacy profiles of existing products are satisfactory, and the only real opportunities are for therapies for use by patients who respond inadequately to existing products.

The October 2011 GERD research piece includes over 71 pages of insight into the gastroesophageal reflux disease market, including statistics for the period 2010-2018. It provides comprehensive analysis of the 13 GERD therapeutic molecules under development in the product pipeline. Those products at an early stage of development have novel mechanisms of action and are focused on addressing the cause of GERD, as well as relief of symptoms such as achlorhydria (absent acid secretion).

Report Details:

http://www.companiesandmarkets.com/Market-Report/gastroesophageal-reflux-disease-(gerd)-therapeutics-pipeline-assessment-and-market-forecasts-to-2018-701812.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.